Prime Capital Investment Advisors LLC Makes New $310,000 Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

Prime Capital Investment Advisors LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,498 shares of the company’s stock, valued at approximately $310,000.

Other large investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its holdings in shares of Krystal Biotech by 50.0% during the second quarter. PNC Financial Services Group Inc. now owns 372 shares of the company’s stock valued at $44,000 after acquiring an additional 124 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Krystal Biotech by 193.3% during the second quarter. Osaic Holdings Inc. now owns 396 shares of the company’s stock valued at $46,000 after acquiring an additional 261 shares in the last quarter. Lazard Asset Management LLC increased its holdings in shares of Krystal Biotech by 52.4% during the second quarter. Lazard Asset Management LLC now owns 713 shares of the company’s stock valued at $82,000 after acquiring an additional 245 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Krystal Biotech by 111.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after acquiring an additional 379 shares in the last quarter. Finally, Almanack Investment Partners LLC. acquired a new position in shares of Krystal Biotech during the third quarter valued at about $52,000. 86.29% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 2,500 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $130.00, for a total value of $325,000.00. Following the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at approximately $1,632,280. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,587 shares of company stock worth $6,535,591. Corporate insiders own 17.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on KRYS shares. Guggenheim upped their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Citigroup increased their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $157.67.

Krystal Biotech Trading Down 3.5 %

Shares of NASDAQ:KRYS opened at $173.62 on Friday. Krystal Biotech, Inc. has a twelve month low of $82.09 and a twelve month high of $189.97. The company’s 50 day moving average is $154.31 and its 200 day moving average is $128.28. The company has a market cap of $4.95 billion, a PE ratio of 2,170.52 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, February 26th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.82. The company had revenue of $42.14 million during the quarter, compared to analysts’ expectations of $27.43 million. During the same quarter in the prior year, the company posted ($1.25) EPS. Equities research analysts predict that Krystal Biotech, Inc. will post 1.61 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).